CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
Baclofen +2 moredrug
Likely dose
Baclofen 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00373295
NCT00373295Phase 2Completed
CompareCT.gov

Effect of Baclofen on Marijuana Withdrawal and Relapse

New York State Psychiatric Institute·interventional·Posted Sep 8, 2006·Updated May 10, 2017

In Brief

A Phase 2 clinical trial evaluating Baclofen, Marijuana, and 1 other intervention for Marijuana Dependence. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarijuana Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 8, 2006
Enrollment StartMay 1, 2006
Primary CompletionJan 1, 2008
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.8 years ago

Interventions

Baclofendrug

Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).

Marijuanadrug

Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.

Placebodrug